41 / 112
39
Monday, 15 June 2015
|
Scientific Programme
WFSBP 2015
P-04-008
Impact of fibromyalgia and presence of anxious and de-
pressive symptoms
María Del Pino Ordovás González, Spain
E. Rodríguez Jiménez, J. Alcalá Partera
P-04-010
Study about Munchhausen syndrome
Mikel Ruiz Feliu, Spain
C. Campos Mangas, A. B. Rodriguez Aliste, M. Haba Sanchez
P-04-012
A rare case of hematohidrosis with schizophrenia
Chytanya Ponangi, India
M. Gowri Devi
P-04-013
Fahr‘s syndrome: A case report
Emilce Blanc, Argentina
M. C. Ballarino, O. A. Porta
P-04-014
Functional impairment, religiosity and depression:
A mixed-methodology study of spinal cord injury patients
in Sri Lanka
Arun Ravindran, Canada
S. Xue, S. Arya, A. Embuldeniya, H. Narammalage, T. da Silva,
S. Williams
P-04-016
New onset anxiety disorder in a patient with possible neu-
rocysticercosis
Andrea Bulbena-Cabre, USA
N. Ramos Dunn, R. Gorman Swift
P-04-019
„I tried to get a bug out of my ear“: A case report of a pa-
tient with delusions of parasitic infestation and the review
of relevant literature
Magdalena Spariosu, USA
D. Coira
P-04-020
„It‘s all in your head“. The psychiatrist‘s role in the diag-
nosis and management of conversion disorder in medical
settings: Case series and literature review
Magdalena Spariosu, USA
D. Coira
P-05
Poster Presentation
12:45–14:15
Muses Foyer
Pharmacological and Brain Stimulation Therapies
Chair:
George Papageorgiou, Greece
Co-Chair: Christos Theleritis, Greece
P-05-001
Concentrations of venlafaxine, mirtazapine and citalopram
in serum and cerebrospinal fluid–a naturalistic approach
Sarah Lammertz, Germany
G. Gründer, S. Tauber, T. Veselinovic, C. Hiemke, M. Paulzen
P-05-003
Serotonin transporter binding ratios predict outcome and
nonadherence to antidepressant in patients with major
depression: A naturalistic follow-up study
San-Yuan Huang, Taiwan
C.-C. Huang, Y.-W. Yeh
P-05-004
Beta-arrestin1&2 are inversely affected by antidepressants
through alterations in ERK1/2-regulated transcription
Sofia Schreiber-Avissar, Israel
M. Golan, G. Schreiber
P-05-005
The optimal dopamine D2/3 receptor occupancy by
antipsychotics in patients with late-life schizophrenia:
A [11C]-Raclopride PET study
Shinichiro Nakajima, Canada
D. Mamo, H. Uchida, T. Suzuki, F. Caravaggio, P. Gerretsen,
T. Rajji, B. Mulsant, B. Pollock, A. Graff-Guerrero
P-05-006
Effectiveness and tolerability of high doses of paliperidone
palmitate in patients with severe schizophrenia
Juan J. Fernández-Miranda, Spain
S. Diaz-Fernandez, E. Tubio-Arcos, A. C. Gamon-Cantero
P-05-007
SerumOrexin-A levels in antipsychotic-treated schizophren-
ic patients and their correlation with metabolic profile
Po-Yu Chen, Taiwan
M.-C. Huang, L.-L. Hwang, C.-H. Chen, V. Mondelli, C.-C.
Chiu, M.-L. Lu